We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Silence Therapeutics to close U.S. operations

Silence Therapeutics to close U.S. operations

June 3, 2011
CenterWatch Staff

London-based Silence Therapeutics, a global RNA interference (RNAi) therapeutics company, has announced plans to close its U.S. operations in conjunction with a recent fundraising round.

The U.S. facility is scheduled to close during the third quarter of 2011. As part of the reorganization, Phil Haworth will step down as CEO once a successor is identified, as previously announced. Recruitment of a new CEO is ongoing.

Silence will continue the following drug development plans: Complete the ongoing phase I trial of Atu027 for treatment of advanced solid cancer in the second half of 2011; initiate a phase Ib trial of Atu027 in particular tumor types in mid-2012; file an IND with the FDA for Atu134 for the treatment of solid tumors in the second half of 2012; and advance pre-clinical development of Atu111 for systemic delivery to the lung for the treatment of pulmonary disease.

 

Global News Drug Sponsors

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing